Key result
Isradipine reduces MAP and increases renal plasma flow ~16% while maintaining stable GFR.
Why the study?
The effects of isradipine on renal hemodynamics and sodium metabolism in patients with mild-to-moderate hypertension were not well characterized.
Does isradipine improve renal hemodynamics and function in patients with mild-to-moderate hypertension?
Comparison
Isradipine 2.5 mg twice daily vs placebo
Design
Double-blind, placebo-controlled study
Follow-up
3 months
Authors
Loading...
Supports isradipine for hypertension with preserved renal hemodynamics; extends dihydropyridine CCB evidence beyond BP reduction.
RCT (n=10)
Double-blind
Does isradipine improve renal hemodynamics and function in patients with mild-to-moderate hypertension?
Low-dose isradipine effectively controls blood pressure while exerting a protective effect on renal hemodynamics by decreasing renal vascular resistance without causing glomerular hyperfiltration.
Francischetti et al. (1992) conducted an RCT in mild-to-moderate hypertension (n=10). Isradipine vs. Placebo was evaluated on Renal hemodynamics and function. Isradipine monotherapy significantly reduced mean arterial pressure and renal vascular resistance, and increased effective renal plasma flow (+16%), while maintaining stable glomerular filtration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: